Efficacy and safety of CagriSema & Retatrutide, CGM benefits beyond T2D, & more!
Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Aroda V, Buzzetti R, Dalskov S et al. “Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type […]
